Central Venous Catheter Related Bloodstream Infection, Central Venous Catheter Thrombosis, Hematologic Malignancy, Solid Tumor
Conditions
Brief summary
Oncology and hemotology patients under anticancer treatments are exposed to increased risks of central venous catheter-related complications due to the underlying cancer and its treament. This prospective observational monocentric french study aims at describing the incidence of such complications, their morbimortality, and analyzing some risk factors in order to contribute to propose some strategies to reduce these complications' rate and consequences
Interventions
DEVICEcentral venous catheter
collection and descriptionof central venous catheter-related complications
Sponsors
Centre Hospitalier Alpes Leman
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
All patients older than 18 years, with solid cancer or hematological malignancy receiving anticancer treatment in the outpatient medical department of Alpes Leman Hospital and having a central venous catheter been placed between the 11th of July 2022, and the 1st of January 2023.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence rate and density of central venous catheter-related complications (infections, thromboses, extravasation) | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Incidence rate of severe central venous catheter-related complications | 6 months |
Contacts
Primary ContactFlorence OBERKAMPF
Outcome results
None listed